MOLECULIN BIOTECH INC (MBRX)
US60855D3098 - Common Stock
MOLECULIN BIOTECH INC
NASDAQ:MBRX (5/3/2024, 7:04:57 PM)
5.02
-0.13 (-2.52%)
Company Profile
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Houston, Texas and currently employs 15 full-time employees. The company went IPO on 2016-06-02. The firm has a pipeline of clinical programs for the treatment of tumors and viruses. The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. Annamycin is in development for the treatment of refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Company Info
MOLECULIN BIOTECH INC
5300 Memorial Dr Ste 950
Houston TEXAS 77007
P: 17133005160
CEO: Walter V. Klemp
Employees: 15
Website: https://moleculin.com/
MBRX News
4 days ago - Moleculin Biotech, Inc.Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...
17 days ago - Moleculin Biotech, Inc.European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)– Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary...
25 days ago - Moleculin Biotech, Inc.Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesAnnamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against established cardiomyocyte cultures...
a month ago - Moleculin Biotech, Inc.Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...
a month ago - Moleculin Biotech, Inc.Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...
a month ago - Moleculin Biotech, Inc.Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...
MBRX Twits
Here you can normally see the latest stock twits on MBRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
